These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25036940)

  • 1. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
    Zhang N; Yang J; Chow SC; Chi E
    J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical test for evaluation of biosimilarity in variability of follow-on biologics.
    Hsieh TC; Chow SC; Liu JP; Hsiao CF; Chi E
    J Biopharm Stat; 2010 Jan; 20(1):75-89. PubMed ID: 20077250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adapted F-test for homogeneity of variability in follow-on biological products.
    Yang J; Zhang N; Chow SC; Chi E
    Stat Med; 2013 Feb; 32(3):415-23. PubMed ID: 22933180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics.
    Zhang N; Yang J; Chow SC; Endrenyi L; Chi E
    Stat Med; 2013 Feb; 32(3):424-33. PubMed ID: 22933127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics.
    Hsieh TC; Chow SC; Yang LY; Chi E
    Stat Med; 2013 Feb; 32(3):406-14. PubMed ID: 22899403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods for assessing interchangeability of biosimilars.
    Chow SC; Yang LY; Starr A; Chiu ST
    Stat Med; 2013 Feb; 32(3):442-8. PubMed ID: 22899372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.
    Shin W; Kang SH
    J Biopharm Stat; 2016; 26(2):227-39. PubMed ID: 25372220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.
    Ebbers HC; van Meer PJ; Moors EH; Mantel-Teeuwisse AK; Leufkens HG; Schellekens H
    Drug Discov Today; 2013 Sep; 18(17-18):872-9. PubMed ID: 23688584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework.
    Karalis VD
    Drug Res (Stuttg); 2016 Jan; 66(1):1-6. PubMed ID: 25894088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
    Chow SC; Hsieh TC; Chi E; Yang J
    J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of the bayesian prior information to evaluation of equivalence of similar biological medicinal products.
    Chiu ST; Liu JP; Chow SC
    J Biopharm Stat; 2014; 24(6):1254-63. PubMed ID: 25032488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific factors and current issues in biosimilar studies.
    Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
    J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
    Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
    BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical methods for assessment of biosimilarity using biomarker data.
    Chow SC; Lu Q; Tse SK; Chi E
    J Biopharm Stat; 2010 Jan; 20(1):90-105. PubMed ID: 20077251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.